Endoscopic Procedures Nose Up in ENT Market
This article was originally published in Start Up
Executive Summary
Ear, nose and throat surgery is the oldest surgical specialty in the US, and until recently, its age was all too apparent. Before the mid 1980s, surgeries for sinusitis were performed in much the same way they'd been done since the turn of the century-through incisions in the face. But in the last 20 years, functional endoscopic sinus surgery was introduced, coupled with CT scanning technologies that have improved the diagnosis of sinusitis. Today, according to US Surgical Procedure Volumes, a report recently published by the Medtech Insight division of FDC-Windhover, the majority of these procedures employ endoscopic techniques performed on an outpatient basis. Now, endoscopic access is the platform upon which start-ups are fixing particular problems in sinus surgeries.
You may also be interested in...
Ethicon Buys Acclarent: Can This Exit Open Up ENT?
Traditionally, the ENT space has been a bit of a technology backwater in terms of device innovation. Indeed, it has been more than a decade since the last major ENT deal, which made Medtronic the sole major strategic player in the ENT space. That dynamic has now changed with J&J/Ethicon's acquisition of Acclarent. Now the question is whether this deal will help open up the ENT space to more M&A activity?
Ethicon Buys Acclarent: Can This Exit Open Up ENT?
Traditionally, the ENT space has been a bit of a technology backwater in terms of device innovation. Indeed, it has been more than a decade since the last major ENT deal, which made Medtronic the sole major strategic player in the ENT space. That dynamic has now changed with J&J/Ethicon's acquisition of Acclarent. Now the question is whether this deal will help open up the ENT space to more M&A activity?
Acclarent: Can Balloons Open Sinuses and the ENT Device Market?
Acclarent is developing interventional technology for the sinuses, targeting a clinical specialty unfamiliar with these techniques, in the hope of expanding an under-served device area. But will ENT surgeons welcome the change?